Skip to main content
 CHANGE IN VISITATION GUIDELINES: Please read before visiting Rutgers Cancer Institute.
Menu

Vemurafenib in patients with BRAF-V600 mutation-positive metastatic melanoma - final overall survival results of the randomized BRIM-3 study